Marinus Pharmaceuticals (NASDAQ:MRNS) Earns Market Perform Rating from JMP Securities

JMP Securities reiterated their market perform rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Thursday morning, MarketBeat.com reports.

A number of other research analysts have also recently weighed in on the stock. StockNews.com upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th. Finally, Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research note on Monday, September 23rd. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals has an average rating of “Hold” and an average target price of $6.07.

Marinus Pharmaceuticals Stock Up 36.9 %

MRNS stock opened at $0.41 on Thursday. The firm has a market cap of $22.31 million, a PE ratio of -0.15 and a beta of 1.14. The business has a 50 day moving average of $1.54 and a 200-day moving average of $1.61. Marinus Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to the consensus estimate of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter last year, the company earned ($0.61) EPS. On average, research analysts expect that Marinus Pharmaceuticals will post -1.93 earnings per share for the current year.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $727,000. Wellington Management Group LLP grew its stake in Marinus Pharmaceuticals by 54.8% during the fourth quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after acquiring an additional 85,455 shares in the last quarter. Vanguard Group Inc. increased its holdings in Marinus Pharmaceuticals by 5.0% during the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock worth $25,366,000 after acquiring an additional 132,689 shares during the period. Acadian Asset Management LLC purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $813,000. Finally, Hussman Strategic Advisors Inc. lifted its stake in Marinus Pharmaceuticals by 14.3% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 10,500 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.